The global rabies treatment market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing awareness about rabies and its prevention, which will lead to an increase in demand for rabies vaccines. The increasing number of cases of animal bites and the lack of availability of post-exposure prophylaxis (PEP) are also driving the growth of this market.
The global rabies treatment market by type includes cell culture vaccines (CCVs), rabies immunoglobulin (RIGs), nerve tissue vaccines (NTVs). CCVs accounted for a share over 50% in 2018 and are expected to maintain their dominance throughout the forecast period owing to their high efficacy rates and low cost per dose. RIGs accounted for a share over 30% in 2018 due to their high efficacy rates, but they are expensive as compared with CCVs. NTVs accounted for a share less than 10% in 2018 due to their lower efficacy rates as compared with CCVs or RIGs, but they have been gaining popularity owing to their low cost per dose as compared with other types.
By application, pre-exposure prophylaxis segment dominated the global rabies treatment market accounting for more than 60% in 2018 due its higher prevalence among humans as compared with post-exposure prophylaxis segment which accounted for less than 40%. Pre-exposure prophylaxis segment is expected maintain its dominance throughout the forecast period owing mainly because it has higher prevalence among humans as compared with post-exposure prophylaxis segment which has lower prevalence among humans; however, post exposure prophylaxis segment is expected grow at a faster rate during 2020 - 2030 due mainly because it has lower incidence rate among animals when compared with pre exposure prophylaxis segment which has higher incidence rate among animals; moreover, there will be an increase in demand from countries where animal bites are common such as India and China during 2020 - 2030 leading towards increased adoption by these countries leading towards increased adoption by these countries leading towards increased adoption by these countries leading towards increased adoption by these countries leading towards increased adoption by these countries leading towards increased adoption by these countries.
Rabies is a viral disease that affects the central nervous system. It is transmitted through saliva from an infected animal to another animal or human. Rabies can be prevented by vaccination, but once symptoms appear, it is fatal without treatment. The rabies virus infects the brain and spinal cord and causes inflammation of the brain tissue, which leads to death.
Industry Growth Insights published a new data on “Rabies Treatment Market”. The research report is titled “Rabies Treatment Market research by Types (Cell culture vaccines (CCVs), Rabies immunoglobulin (RIGs), Nerve tissue vaccines (NTVs)), By Applications (Pre-exposure prophylaxis, Post-exposure prophylaxis), By Players/Companies Cadila Healthcare, GlaxoSmithKline, Merial, Sanofi, Merck, Pfizer, Bayer, AstraZeneca, Amneal Pharmaceuticals, Anergis”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rabies Treatment Market Research Report
By Type
Cell culture vaccines (CCVs), Rabies immunoglobulin (RIGs), Nerve tissue vaccines (NTVs)
By Application
Pre-exposure prophylaxis, Post-exposure prophylaxis
By Companies
Cadila Healthcare, GlaxoSmithKline, Merial, Sanofi, Merck, Pfizer, Bayer, AstraZeneca, Amneal Pharmaceuticals, Anergis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Rabies Treatment Market Report Segments:
The global Rabies Treatment market is segmented on the basis of:
Types
Cell culture vaccines (CCVs), Rabies immunoglobulin (RIGs), Nerve tissue vaccines (NTVs)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pre-exposure prophylaxis, Post-exposure prophylaxis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cadila Healthcare
- GlaxoSmithKline
- Merial
- Sanofi
- Merck
- Pfizer
- Bayer
- AstraZeneca
- Amneal Pharmaceuticals
- Anergis
Highlights of The Rabies Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cell culture vaccines (CCVs)
- Rabies immunoglobulin (RIGs)
- Nerve tissue vaccines (NTVs)
- By Application:
- Pre-exposure prophylaxis
- Post-exposure prophylaxis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rabies Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rabies treatment is a series of steps that are taken to prevent the spread of rabies. Rabies treatment may include:nn-Acute phase: This involves taking measures to prevent the rabies virus from spreading, such as giving antibiotics and painkillers. If the person has symptoms, they will be given an injection to help them feel better.nIf the person develops a fever or seizures, they will be admitted into hospital for further care. n-Post-exposure prophylaxis (PEP): PEP is a series of injections given after someone has been exposed to rabies virus in order to protect them from getting sick. The first injection should be given within 72 hours after exposure, and subsequent injections should be given every four weeks while receiving regular health checkups. nn-Treatment: If someone gets infected with rabies, their doctor will give them an antiviral drug called Rabeprazole which can stop the virus from multiplying in their body and help reduce symptoms such as fever and headache
Some of the major players in the rabies treatment market are Cadila Healthcare, GlaxoSmithKline, Merial, Sanofi, Merck, Pfizer, Bayer, AstraZeneca, Amneal Pharmaceuticals, Anergis.
The rabies treatment market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rabies Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rabies Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rabies Treatment Market - Supply Chain
4.5. Global Rabies Treatment Market Forecast
4.5.1. Rabies Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rabies Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Rabies Treatment Market Absolute $ Opportunity
5. Global Rabies Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Rabies Treatment Market Size and Volume Forecast by Type
5.3.1. Cell culture vaccines (CCVs)
5.3.2. Rabies immunoglobulin (RIGs)
5.3.3. Nerve tissue vaccines (NTVs)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Rabies Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Rabies Treatment Market Size and Volume Forecast by Application
6.3.1. Pre-exposure prophylaxis
6.3.2. Post-exposure prophylaxis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Rabies Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Rabies Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Rabies Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rabies Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rabies Treatment Demand Share Forecast, 2019-2026
9. North America Rabies Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rabies Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rabies Treatment Market Size and Volume Forecast by Application
9.4.1. Pre-exposure prophylaxis
9.4.2. Post-exposure prophylaxis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Rabies Treatment Market Size and Volume Forecast by Type
9.7.1. Cell culture vaccines (CCVs)
9.7.2. Rabies immunoglobulin (RIGs)
9.7.3. Nerve tissue vaccines (NTVs)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Rabies Treatment Demand Share Forecast, 2019-2026
10. Latin America Rabies Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rabies Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rabies Treatment Market Size and Volume Forecast by Application
10.4.1. Pre-exposure prophylaxis
10.4.2. Post-exposure prophylaxis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Rabies Treatment Market Size and Volume Forecast by Type
10.7.1. Cell culture vaccines (CCVs)
10.7.2. Rabies immunoglobulin (RIGs)
10.7.3. Nerve tissue vaccines (NTVs)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Rabies Treatment Demand Share Forecast, 2019-2026
11. Europe Rabies Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rabies Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rabies Treatment Market Size and Volume Forecast by Application
11.4.1. Pre-exposure prophylaxis
11.4.2. Post-exposure prophylaxis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Rabies Treatment Market Size and Volume Forecast by Type
11.7.1. Cell culture vaccines (CCVs)
11.7.2. Rabies immunoglobulin (RIGs)
11.7.3. Nerve tissue vaccines (NTVs)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Rabies Treatment Demand Share, 2019-2026
12. Asia Pacific Rabies Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rabies Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rabies Treatment Market Size and Volume Forecast by Application
12.4.1. Pre-exposure prophylaxis
12.4.2. Post-exposure prophylaxis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Rabies Treatment Market Size and Volume Forecast by Type
12.7.1. Cell culture vaccines (CCVs)
12.7.2. Rabies immunoglobulin (RIGs)
12.7.3. Nerve tissue vaccines (NTVs)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Rabies Treatment Demand Share, 2019-2026
13. Middle East & Africa Rabies Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Rabies Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rabies Treatment Market Size and Volume Forecast by Application
13.4.1. Pre-exposure prophylaxis
13.4.2. Post-exposure prophylaxis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Rabies Treatment Market Size and Volume Forecast by Type
13.7.1. Cell culture vaccines (CCVs)
13.7.2. Rabies immunoglobulin (RIGs)
13.7.3. Nerve tissue vaccines (NTVs)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Rabies Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Rabies Treatment Market: Market Share Analysis
14.2. Rabies Treatment Distributors and Customers
14.3. Rabies Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Cadila Healthcare
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merial
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bayer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AstraZeneca
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Amneal Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Anergis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
